Next Article in Journal
The Effect of Electrospun Gelatin Fibers Alignment on Schwann Cell and Axon Behavior and Organization in the Perspective of Artificial Nerve Design
Next Article in Special Issue
Inflammatory and Other Biomarkers: Role in Pathophysiology and Prediction of Gestational Diabetes Mellitus
Previous Article in Journal
Quantitative Structure-Antioxidant Activity Models of Isoflavonoids: A Theoretical Study
Previous Article in Special Issue
Circulating Levels of sFlt1 Splice Variants as Predictive Markers for the Development of Preeclampsia
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(6), 12907-12924; doi:10.3390/ijms160612907

From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications

1
Maternal and Fetal Health Research Centre, Institute of Human Development, University of Manchester, Manchester M13 9WL, UK
2
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Philip Newton Baker
Received: 1 May 2015 / Revised: 26 May 2015 / Accepted: 28 May 2015 / Published: 8 June 2015
(This article belongs to the Special Issue Prediction, Diagnostics and Prevention of Pregnancy Complications)
View Full-Text   |   Download PDF [710 KB, uploaded 8 June 2015]

Abstract

Complications of pregnancy represent a significant disease burden, with both immediate and lasting consequences for mother and baby. Two key pregnancy complications, fetal growth restriction (FGR) and preeclampsia (PE), together affect around 10%–15% of all pregnancies worldwide. Despite this high incidence, there are currently no therapies available to treat these pregnancy disorders. Early delivery remains the only intervention to reduce the risk of severe maternal complications and/or stillbirth of the baby; however early delivery itself is associated with increased risk of neonatal mortality and morbidity. As such, there is a pressing need to develop new and effective treatments that can prevent or treat FGR and PE. Animal models have been essential in identifying and screening potential new therapies in this field. In this review, we address recent progress that has been made in developing therapeutic strategies for pregnancy disorders, some of which are now entering clinical trials. View Full-Text
Keywords: pregnancy; fetal growth restriction; preeclampsia; preclinical trials in pregnancy pregnancy; fetal growth restriction; preeclampsia; preclinical trials in pregnancy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Cottrell, E.C.; Sibley, C.P. From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications. Int. J. Mol. Sci. 2015, 16, 12907-12924.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top